Co-Diagnostics reports Q3 and YTD 2024 results.
The company reported strong financial results driven by its mPCR platform, though it provided lower than expected fiscal 2025 revenue guidance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day